The Drug Precursors Unit is an administrative cell composed of representatives of the Federal Agency for Medicines and Health Products and the Customs and Excise authority.
The Drug Precursors Unit was established in 1993 as a monitoring body to ensure compliance with the Royal Decree of 26 October 1993 laying down measures to prevent the diversion of certain substances for the illicit manufacture of narcotics and psychotropic substances. This Royal Decree was previously a transposition of Council Regulation (EEC) No 3677/90 and Commission Regulation (EEC) No 3769/92, but the new measures for legal control are set out in the following EU Regulations:
1. REGULATIONS
CONSOLIDATED VERSION OF REGULATION (EC) NO 273/2004 (original text) of the European Parliament and the Council of 11 February 2004 on drug precursors (Text with EEA relevance)
This Regulation lays down harmonised measures for control and monitoring, within the Community, of certain substances frequently used for the illicit manufacture narcotic drugs or psychotropic substances with a view to preventing the diversion of such substances
CONSOLIDATED VERSION OF COUNCIL REGULATION (EC) NO 111/2005 (original text) of 22 December 2004 laying down rules for the monitoring of trade between the Community and third countries in drug precursors.
This Regulation lays down the rules for monitoring of trade between the Community and third countries in certain substances frequently used in the illicit manufacture of narcotic drugs or psychotropic substances for the purpose of preventing the diversion of such substances. The Regulation applies to imports, exports and intermediary activities.
COMMISSION DELEGATED REGULATION (EU) 2015/1011 of 24 April 2015 supplementing Regulation (EC) No 273/2004 of the European Parliament and of the Council on drug precursors and Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade between the Union and third countries in drug precursors, and repealing Commission Regulation (EC) No 1277/2005.
You can find here a list of the countries referred to in Article 10 of this Regulation.
COMMISSION IMPLEMENTING REGULATION (EU) 2015/1013 of 25 June 2015 laying down rules in respect of Regulation (EC) No 273/2004 of the European Parliament and of the Council on drug precursors and of Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade between the Union and third countries in drug precursors.
COMMISSION DELEGATED REGULATION (EU) 2016/1443 of 29 June 2016 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances.
COMMISSION DELEGATED REGULATION (EU) 2018/729 of 26 February 2018 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances.
COMMISSION DELEGATED REGULATION (EU) 2020/1737 of 14 July 2020 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances.
COMMISSION DELEGATED REGULATION (EU) 2022/1518 of 29 March 2022 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances.
COMMISSION DELEGATED REGULATION (EU) 2023/196 of 25 November 2022 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances.
2. EXPLANATORY NOTES
1. Explanatory Note on export authorisation of scheduled substances of Category 4.
3. New CN code of APAAN(Alpha-phenylacetoacetonitrile)
4. The FAMHP ‘s new financing law
5. Important information on GBL (gamma-butyrolactone) and/or 1.4-BD (1.4‑butanediol)
6. Explanatory Note on Delegated Regulation (EU) 2022/1518
7. Reminder: customer declaration
8. Explanatory Note on Delegated Regulation (EU) 2023/196